SightGlass Vision CEO, Andrew Sedwick, has outlined the origins of technology that helps to limit the progression of myopia through specialised spectacle lenses.
The technology harnessed by SightGlass Vision’s myopia management DOT lenses is based on a hypothesis around contrast management by professors based at the University of Washington, Sedgwick explained to OT.
“They found that reducing contrast slightly can have a very beneficial effect on the slowing of myopia,” he shared.
The technology utilised in the lenses is anchored in research completed through two main studies. The first, Sedgwick shared, is a four-year US-based study which reported “very good” efficacy and safety during that period, with a one-year follow-up reporting no rebound effect.
Sedgwick highlighted that this CYPRESS study reported the slowing of the progress of myopia for 75% of participants during the first year.
The second is a China-based study which presented its 18-month findings recently, reporting that 57% of the children in the study had no meaningful clinical progression at all in that period.
Reflecting on SightGlass Vision’s research supporting its lenses, Sedgwick said: “We are relatively unusual in studying children as young as six, and we have had very strong results in those younger children which we are very proud of.
“The younger we start treatment the better – every dioptre matters.”
Watch the full interview above.
Comments (0)
You must be logged in to join the discussion. Log in